Skip to Contents
IR News
  1. Veritas In Silico Inc.
  2. INVESTOR RELATIONS
  3. IR News

IR News

  • Aug 5, 2026 Financial Briefing Materials - FY2026 Second Quarter pdf （3,532KB）
  • Aug 5, 2026 Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP] pdf （284KB）
  • Aug 3, 2026 Joint Patent Application Filed for lncRNA-Targeting Drugs pdf （233KB）
  • Jul 13, 2026 Personnel Changes in Executive Officer pdf （224KB）
  • Jul 3, 2026 Notice regarding Date and Time of FY2026 Q2 Earnings Release pdf （51KB）
  • Jun 11, 2026 Our latest company research and analysis report pdf （628KB）
  • May 18, 2026 Pre-Consultation Meeting with Pharmaceuticals and Medical Devices Agency (PMDA) towards the Commercialization of the Drug Delivery System "Perfusio" pdf （222KB）
  • May 11, 2026 Financial Results - FY2026 First Quarter pdf （1,178KB）
  • May 11, 2026 Non-consolidated Financial Results for the Three Months Ended March 31,2026 [Under Japanese GAAP] pdf （247KB）
  • May 11, 2026 Notice of Extraordinary Loss Due to Impairment Accounting pdf （200KB）
  • May 11, 2026 SpiroChem and Veritas In Silico entered into Joint Research Agreement to Initiate the Discovery of Next Generation mRNA Binding Chemical Matter pdf （355KB）
  • Apr 27, 2026 Announcement of the Publication of a Research Article on AISLAR, a Method for Streamlining Screening That Supports Our AI-Driven Drug Discovery pdf （342KB）
  • Apr 16, 2026 Notice of Scheduled Date and Time for the Announcement of Q1 Financial Results for the Fiscal Year Ending December 2026 pdf （243KB）
  • Apr 13, 2026 Termination of Collaborative Drug Discovery Research with Takeda on mRNA-Targeted Small-Molecule Drugs pdf （162KB）
  • Mar 26, 2026 Greetings from Our Newly Appointed Director and Audit & Supervisory Board Member pdf （202KB）
  • Mar 25, 2026 Report and Resolution at the 10th Annual General Shareholders’ Meeting pdf （263KB）
  • Feb 19, 2026 Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member pdf （310KB）
  • Feb 12, 2026 Financial Results - Fiscal Year Ended December 31, 2025 pdf （3,422KB）
  • Feb 12, 2026 Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP] pdf （380KB）
  • Feb 12, 2026 Company Presentation pdf （4,263KB）
  • Jan 26, 2026 SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter pdf （255KB）
  • Jan 19, 2026 The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS pdf （326KB）
  • Jan 5, 2026 Upgrading the Drug Discovery Platform ibVIS to aibVIS pdf （539KB）
  • Dec 22, 2025 Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline pdf （243KB）
  • Dec 15, 2025 Company Presentation pdf （6,054KB）
  • Dec 15, 2025 Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio" pdf （446KB）
  • Nov 17, 2025 Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction pdf （255KB）
  • Nov 11, 2025 Financial Results - Fiscal Year Ending December 2025, 3rd Quarter　 pdf （3,053KB）
  • Nov 11, 2025 Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP] pdf （256KB）
  • Nov 11, 2025 Organizational Reforms and Personnel Changes pdf （248KB）
  • Nov 7, 2025 Fisco Releases Corporate Research Report Based on Financial Data as of August 2025 pdf （800KB）
  • Nov 4, 2025 Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic pdf （227KB）
  • Oct 14, 2025 Revised Financial Forecast for FY2025 pdf （285KB）
  • Sep 29, 2025 Relocation of the Shin-Kawasaki Research Institute pdf （224KB）
  • Sep 24, 2025 The Jikei University School of Medicine and VIS announce Start of Joint Research for Fundamentally Enhancing Therapeutic Effects of Pharmaceuticals pdf （295KB）
  • Sep 16, 2025 Nomination of a Candidate for Independent Outside Director pdf （232KB）
  • Aug 4, 2025 Non-consolidated Financial Results for the Six Months Ended June 30, 2025 [Under Japanese GAAP] pdf （333KB）
  • Aug 4, 2025 Financial Results - Fiscal Year Ended December 31, 2025, 2nd Quarter pdf （8,018KB）
  • Jul 28, 2025 Patent owned by Veritas In Silico receives Notice of Allowance in the U.S. pdf （211KB）
  • Jul 3, 2025 Mitsubishi Gas Chemical and VIS Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs pdf （235KB）
  • Jun 16, 2025 Determination of Target Disease for mRNA-Targeted Nucleic Acid Drug for In-house Pipeline pdf （265KB）
  • May 23, 2025 Shionogi and Veritas In Silico Announce Milestone Achievement in Joint Drug Discovery Research of mRNA-targeted Small Molecules pdf （238KB）
  • May 9, 2025 Financial Results - Fiscal Year Ended December 31,2025, 1st Quarter pdf （2,210KB）
  • May 9, 2025 Non-consolidated Financial Results for the Three Months Ended March 31,2025 [Under Japanese GAAP] pdf （312KB）
  • Feb 20, 2025 Reduction of Capital Stock (Capital Reduction) pdf （229KB）
  • Feb 20, 2025 Appointing Candidates for Director and Alternate Audit & Supervisory Board Member pdf （231KB）
  • Feb 20, 2025 Organizational Reforms and Personnel Changes pdf （321KB）
  • Feb 13, 2025 Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Under Japanese GAAP] pdf （319KB）
  • Feb 13, 2025 Financial Results - Fiscal Year Ended December 31, 2024 pdf （6,565KB）
  • Feb 13, 2025 Company Presentation pdf （9,803KB）
  • Dec 30, 2024 Patent owned by Veritas In Silico to Become Effective in Europe pdf （198KB）
  • Dec 23, 2024 Liverpool ChiroChem and VIS to Enter into a Collaboration Development & Commercialization Agreement for mRNA-targeted Small Molecule Drugs pdf （209KB）
  • Dec 13, 2024 Company Presentation pdf （8,876KB）
  • Dec 13, 2024 Revised Financial Forecast for FY2024 pdf （247KB）
  • Nov 13, 2024 Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Under Japanese GAAP] pdf （244KB）
  • Nov 13, 2024 Fiscal Year Ending December 2024, 3rd Quarter, Financial Results pdf （3,522KB）
  • Nov 13, 2024 Organizational Reforms and Personnel Changes of General Managers pdf （230KB）
  • Oct 9, 2024 Mitsubishi Gas Chemical and Veritas In Silico, Sign MOU on Joint Business of Research and Development of RNA-Targeted Drugs pdf （189KB）
  • Oct 9, 2024 Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development pdf （303KB）
  • Sep 24, 2024 Notification regarding Achievement of Milestone in Joint Drug Discovery Research with Shionogi & Co., Ltd. pdf （202KB）
  • Sep 3, 2024 [Delayed] Interim Financial Results - FY2024 1H pdf （3,610KB）
  • Aug 5, 2024 Non-consolidated Financial Results for the Six Months Ended June 30, 2024 [Under Japanese GAAP] pdf （245KB）
  • Jul 31, 2024 Announcement of the opening of an English-language IR website pdf （164KB）

VIEW IR NEWS

  • header-content
  • header-content

  • CLOSE
  • MENU

サイト内検索

If you agree to the use of cookies, please click the "Agree" button.
If you do not agree, please do not use this site. For details, please refer to the following page.

Privacy Policy

Agree

  • footer-content